Quality of life in the first weeks of (neo)adjuvant systemic therapy of patients with breast cancer – first data from MaLife, a pilot project of the TMK Registry Group.

Marschner, N., Tesch, H., Behringer, J., Sandner, R., Spring, L., Jänicke, M., 2013.

Onkologie 36 (suppl 7)(V355), 96. doi:10.1159/000356365

Studie: TMK; Indikation: Mammakarzinom; Jahr: 2013; Veranstaltung: DGHO; Journal: Onkologie

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com